Which is more important for universities and colleges-Teaching or Research?

In universities here, research is the main criterion for appointment as well as promotion and  good researchers generally pay less attention to teaching. However, I feel one cannot remain abreast with recent developments in the field without being involved in research and the teaching will be very dogmatic. Also, only researchers can infuse a spirit of enquiry and innovation in their students.So, there is a need to balance the 2, not their separation. Quality of teaching must be an equal, if not more important, criterion for grading and promotion of teachers. What do you say?

Online access results in more citations?

Science 20 February 2009:Vol. 323. no. 5917, p. 1025DOI: 10.1126/science.1154562

Brevia
Open Access and Global Participation in Science

James A. Evans and Jacob Reimer
Previous investigations into the impact of open-access journals on subsequent citations confounded open and electronic access and failed to track availability over time. With new data, we separated these effects. We demonstrate that a journal receives a modest increase in citations when it comes online freely, but the jump is larger when it first comes online through commercial sources. This effect reverses for poor countries where free-access articles are much more likely to be cited. Together, findings suggest that free Internet access widens the circle of those who read and make use of scientists' investigations.

Free online availability of scientific articles increases the likelihood of papers getting cited, especially in the developing world and in the biomedical sciences, according to this new study published in Science.
The question of whether open access drives citations has been hotly contested among scientists, policymakers, and editors, with several recent studies coming down on different sides of the debate. In the most extensive study to date -- covering around 26 million articles from more than 8,000 journals published from 1998 to 2005 -- University of Chicago sociologist James Evans, together with neurobiology grad student Jacob Reimer, found that making an article freely available on the internet increased the number of citations, but only by about 8%, which was far less than some previous claims. When the authors looked just at poorer countries, however, they found that the influence of open access was more than twice as strong. For example, in Bulgaria and Chile, researchers cited nearly 20% more open access articles, and in Turkey and Brazil, the number of citations rose by more than 25%. Free online availability "is not a huge driver of science in the first world, but it shapes parts of science in the rest of world," Evans told The Scientist. "Scientists and scholars in poorer countries are disproportionately citing articles that are freely available to them." "The results make a lot of sense," Gunther Eysenbach, a health policy and e-health researcher at the University of Toronto who was not involved in the research, told The Scientist. "In countries with lower income, the [open access] effect is bigger than in countries where researchers have access to the literature anyway -- that's quite intuitive." Stevan Harnad, an open access advocate and cognitive neuroscientist at the University of Quebec at Montreal who was not involved with the study, said that the authors should have compared public and private institutions closer to home to test whether the same effect was true in the developed world. "[Evans] looked at the big picture, but he could have cut the cake a bit finer and found the same effects if he compared the Harvards and the have nots," Harnad told The Scientist. "It's a shame that with such rich data he didn't look at other such important and pressing questions." Free online access conferred the greatest citation advantage in the life sciences, and no significant influence in three areas -- chemistry, physics and the social sciences -- which the authors chalked up to a culture of pre-print databases and personal archiving. Although open access had a modest overall influence, commercial online availability had an even greater effect. This indicates that most researchers are turning to the internet to find papers, though they may rely largely on institutional subscriptions, said Evans. "The larger influence is of things being online," whether commercially or not. Philip Davis, a Cornell University grad student in science communications who also studies the effects of open access on citation records, praised the article's size and breadth, but noted that Evans "can't measure the article-level details, he can only look at the journal level." The study lumped together articles from entire journal volumes, which overlooks author-pay models that make some but not all articles in a journal freely available, Davis noted.

First available oral fungicidal agent.

Kishor Wasan, a pharmacologist at the University of British Columbia, needed a negative control. It was 2000, and he was investigating a new way to deliver anti-fungal drugs in pill form, generally cheaper and easier to administer than intravenous injections. "I said, 'Let's take a drug I know doesn't work'," Wasan recalls. He turned to amphotericin B, an antifungal membrane disruptor that Wasan had studied a decade earlier for his PhD, and is not normally absorbed by the body when administered orally. He embedded amphotericin B and a batch of other drugs into his newly devised lipid-based delivery vehicle, and fed them to rats. This turned out to be perhaps one of the worst negative control experiments ever - but a lucky break for Wasan.

Compared to the other drug treatments, the rats on amphotericin B had the highest blood levels and lowest kidney levels of the drug, indicating that the body more readily absorbed amphotericin B than any other drug. What's more, oral amphotericin B seemed to bypass the renal toxicity normally associated with intravenous forms of the drug (Antimicrob Agents Chemother, 47:3339-42, 2003).

Wasan was bewildered: "I thought, what the heck is going on?" Further experiments showed the drug was actually working: Amphotericin B fed to rats wiped out Aspergillus fumigatus infections (Drug Dev Ind Pharm, 33:703-7, 2007), and 90% ofCandida albicans kidney infections, which is similar to the 95% success rate seen with intravenous delivery. All with no renal toxicity. "The fact that we've got an oral formulation that's mimicking IV - that's a major finding," Wasan says.

"Amp-B is basically the best antifungal agent we have; the problem with it is that it has to be given IV and it's toxic," says David Stevens, a clinical mycologist at the Santa Clara Valley Medical Center in San Jose, Calif. Eliminate the need for IV and "they've got half the battle solved," he adds. "And if it's less toxic, it's a home run."

Amphotericin B in poppable pill form could treat systemic fungal infections, particularly in patients with cancer or HIV/AIDS. This may make it highly profitable in the developed world, but it can also combat parasitic infections, such as trypanosomiasis and visceral leishmaniasis, that are more prevalent in developing nations. "We've got a first-world need where we can make money," says Wasan, "and a third-world need where you can sell the drug at a subsidized cost."

To commercialize his formulation, in 2007 Wasan teamed up with the UBC chapter of Universities Allied for Essential Medicines, an international organization that aims to improve access to medicines and research on neglected diseases at academic research institutions. In May 2008, Wasan licensed his oral amphotericin B formulation to iCo Therapeutics, a Vancouver-based biotech company, which agreed to make the drug available at a subsidized cost to combat leishmaniasis in developing nations. It's a "win-win" situation, says John Clement, iCo's chief business officer.

Wasan's amphotericin B formulation could prove to be the world's first available oral fungicidal agent. (Pfizer's oral antifungal Diflucan (fluconazole) stops fungal growth but does not kill the infectious agent.) But Raleigh, NC-based BioDelivery Sciences International (BDSI) has its own oral formulation of amphotericin B based on its patented Bioral delivery technology, which wraps the drug in a coiling structure of alternating lipid layers, currently in phase I trials. (Clearly, amphotericin B is more 'oral-izable' than originally believed.) Still, Wasan thinks his drug, in preclinical trials, should have an advantage. His formulation solubilizes the drug in a glyceride-based liquid, whereas Bioral relies on a liposomal suspension, which can be difficult to bring up to a commercial scale, he notes.

Raphael Mannino, BDSI's chief scientific officer, disagrees. "This is a very simple manufacturing process," he says. What's more, BDSI's formulation is effective, nontoxic, and "even in suspension, we have very long stability of our product," he says.

The irony of Wasan's drug discovery, he notes, is that he didn't even want to study amphotericin B again after finishing his PhD; he only resorted to the drug because he expected it to fail. "Am I lucky as hell? Yes. Did I think it was going to work? No. Am I fully believing it? Well, human studies will be needed to play this out."

Becoming a scientist

What qualities do you need to succeed in biomedical research? Some of the world's most prominent biomedical researchers may surprise you with their answers. As you'll see in their video responses, they say that intelligence alone is insufficient; success in science also depends on several other qualities.
Visit http://www.hhmi.org/becoming/

Some Myth related to learning -- their scientific basis??

Myth 1: You remember 10% of what you read, 20% of what you hear, 30% of what you see and 90% of what you do.

The findings can be traced to one D.G. Treichler, an employee of Mobil Oil Company, who put forth these figures in 1967.

However, the NTL Institute for Applied Behavioral Science has laid claim to the figures, saying they are based on research in the early sixties and bizarrely adding that ‘we no longer have - nor can we find - the original research that supports the numbers’.

Though, there are many arguments against these figures, one that is most obvious is that all the percentages are perfectly round. What research into human behaviour ever resulted in four different round numbers?

Myth 2: In communication, only 7% of the meaning is conveyed through the speaker’s words, 55% through his facial expressions and the rest 38% through tone of voice.

The findings are attributed to research done by Mehrabian but, in reality, they are just a distorted version of what Mehrabian himself has to say on his website. He expresses the results of his research in the form of an equation:

Total liking = 7% verbal liking + 38% vocal liking + 55% facial liking

He explains that “this and other equations regarding relative importance of verbal and nonverbal messages were derived from experiments dealing with communications of feelings and attitudes (i.e. like-dislike). Unless a communicator is talking about their feelings or attitudes, these equations are not applicable.”

Myth 3: We use 10% of our brain

Scientists have tried for years to change this misconception. They have clearly stated that there is no scientific evidence to suggest that we use only 10% of our brains. In fact it is very hard to say what using just 10% of your brain means.

It strains credulity to think that God would have permitted squandering of resources on a scale necessary to build and maintain such a massively underutilized organ.

Secondly, losing far less than 90 percent of the brain to accident or disease has catastrophic consequences. Various medical tests reveal that there does not seem to be any area of the brain that can be destroyed without leaving the patient with some kind of functional deficit.

Likewise, electrical stimulation of points in the brain during neurosurgery has failed so far to uncover any dormant areas where no percept, emotion or movement is elicited by applying these tiny currents.

Exclusive Academic Pharma Research Website

"www.pharmaresearch.in" is the India's 1st exclusive and free Pharma website for academic research to bridge the existing lacuna between academic institutes and Pharma industry association and to provide the research problems to all research scholars by industrial experts for the research deliberations and rational solutions. The research theme will be actual research problems/research in the areas of R&D, F&D, Pharmacology, Biotechnology and Herbal drug Technology units and thus it will offer a paramount opportunity to each of the research scholars to show their potentials according to need of research in Pharma industry.
Apart from this, website will also provide as a sole destination to many information On latest Pharma news about seminars & workshops in India, Free access to Pharma journals, Indian Pharma publications, Impact factor for Pharma journals, Pharmaweb links, Free Pharma Software, Sources of financial assistance for research project in India, sources for travel grants, List of CROs in India, List of facilities for instrumental analysis, List of facilities for herbarium and plant identification and many more Pharma updates.